Related Experiment Video

Updated: Jul 16, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease

Colleen Olive1

  • 1The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. Colleen.Olive@qimr.edu.au

Current Opinion in Molecular Therapeutics
|March 3, 2007
PubMed

Insights

Group A Streptococcus (GAS) causes over 500,000 deaths annually, primarily from rheumatic fever and heart disease. This review explores subunit vaccines targeting the M protein to overcome strain diversity and prevent GAS infections.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Group A Streptococcus (GAS) infection leads to over 500,000 deaths yearly, mainly due to rheumatic fever (RF) and rheumatic heart disease (RHD).
  • GAS-associated diseases disproportionately affect less developed regions and indigenous populations.
  • The GAS M protein is a key target for vaccine development but faces challenges due to strain diversity and potential autoimmunity via molecular mimicry.

Purpose of the Study:

  • To review the development of a safe and effective Group A Streptococcus (GAS) vaccine.
  • To explore subunit vaccine approaches targeting the M protein.
  • To address challenges in GAS vaccine development, including strain diversity and molecular mimicry.

Main Methods:

  • Review of current research on GAS vaccine development.
  • Focus on subunit vaccine strategies targeting the M protein.
  • Examination of various vaccine delivery technologies for M-protein-based vaccines.

Main Results:

  • Widespread diversity of GAS strains and M protein types is a major obstacle for vaccine efficacy.
  • Potential for vaccine-induced autoimmunity due to molecular mimicry between M protein and host tissues is a significant concern.
  • Research is actively pursuing safe GAS vaccine candidates that induce broad-spectrum protective immunity.

Conclusions:

  • Subunit vaccine approaches targeting the M protein are a promising strategy for preventing GAS infection, RF, and RHD.
  • Overcoming M protein diversity and ensuring vaccine safety are critical for successful GAS vaccine development.
  • Continued research into various vaccine delivery technologies is essential for advancing GAS vaccine candidates.

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis06:57

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...